And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.

Declan Doogan Biography and Net Worth

Director of Biohaven

Dr. Declan Doogan, MD, co-founder of Juvenescence, was driven to start the company because he believes we all can do better in managing health as we get older.

Dr. Doogan, the Chief Medical Officer of Juvenescence, has more than 30 years experience in the global pharmaceutical industry. He was Head of Worldwide Drug Development at Pfizer, working in the US, UK and Japan. Dr. Doogan was also head of R&D at Amarin where he helped raise $100m to fund the reorganization and portfolio realignment leading to the NDA approval for Vascepa (icosapent ethyl) for elevated triglycerides.

During his career, Declan has engaged in activities to promote excellence in pharmaceutical medicine and sits on the boards of several biotechnology companies and multiple pharmaceutical companies. He is Chairman and co-founder of Biohaven Pharmaceuticals, Portage Biotech, and PHPrecisionmed.

Dr. Doogan graduated Medicine from Glasgow University, is a Fellow of the Royal College of Physicians and Surgeons of Glasgow, and holds an honorary degree of DSc from the University of Kent in the UK. He is visiting professor at Glasgow University.

Dr. Doogan practices what he preaches; staying healthy by vigorous exercise, dietary modification, nutritional supplementation and by having a rich social and family life.

What is Declan Doogan's net worth?: The estimated net worth of Declan Doogan is at least $19.22 million as of June 15th, 2020. Dr. Doogan owns 373,913 shares of Biohaven stock worth more than $19,219,128 as of November 5th. This net worth estimate does not reflect any other assets that Dr. Doogan may own. Learn More about Declan Doogan's net worth.
How do I contact Declan Doogan?: The corporate mailing address for Dr. Doogan and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on Declan Doogan's contact information.
Has Declan Doogan been buying or selling shares of Biohaven?: Declan Doogan has not been actively trading shares of Biohaven during the last ninety days. Most recently, Declan Doogan sold 24,525 shares of the business's stock in a transaction on Monday, November 29th. The shares were sold at an average price of $112.80, for a transaction totalling $2,766,420.00. Learn More on Declan Doogan's trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

Declan Doogan Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/29/2021	Sell	24,525	$112.80	$2,766,420.00
11/16/2021	Sell	37,740	$116.65	$4,402,371.00
6/15/2020	Sell	80,000	$66.73	$5,338,400.00	373,913
6/12/2020	Sell	160,000	$66.00	$10,560,000.00	373,913
4/16/2019	Sell	88,825	$58.42	$5,189,156.50	373,913
4/12/2019	Sell	38,825	$53.92	$2,093,444.00	373,913
3/26/2019	Sell	11,175	$53.69	$599,985.75	373,913
3/22/2019	Sell	5,351	$53.66	$287,134.66	373,913
3/1/2019	Sell	50,595	$47.17	$2,386,566.15	394,083
2/27/2019	Sell	27,045	$45.02	$1,217,565.90	394,083
2/19/2019	Sell	2,078	$45.48	$94,507.44
2/13/2019	Sell	40,000	$44.31	$1,772,400.00
6/5/2018	Sell	89,216	$35.25	$3,144,864.00
6/1/2018	Sell	110,784	$35.03	$3,880,763.52	463,913
5/30/2018	Sell	842	$35.00	$29,470.00	463,913
1/18/2018	Sell	128,058	$26.95	$3,451,163.10	2,583,289
1/12/2018	Sell	121,942	$26.78	$3,265,606.76
1/10/2018	Sell	40,362	$27.69	$1,117,623.78

Declan Doogan Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $51.40

$49.48

$51.41

50 Day Range

MA: $46.04

$35.72

$53.73

2 Week Range

Now: $51.40

$26.80

$62.21

Volume

492,722 shs

Average Volume

1,148,214 shs

Market Capitalization

$4.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

The Final Frontier

From Porter & Company | Ad

Here’s the full story for you.